Analyzing Generex Biotechnology (OTCMKTS:GNBT) and Acelyrin (NASDAQ:SLRN)

Generex Biotechnology (OTCMKTS:GNBT) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.

Insider and Institutional Ownership

87.3% of Acelyrin shares are held by institutional investors. 35.2% of Generex Biotechnology shares are held by company insiders. Comparatively, 13.6% of Acelyrin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Generex Biotechnology and Acelyrin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Generex Biotechnology	N/A	N/A	N/A
Acelyrin	N/A	-46.10%	-41.46%

Valuation & Earnings

This table compares Generex Biotechnology and Acelyrin”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generex Biotechnology	$2.66 million	0.00	-$33.33 million	N/A	N/A
Acelyrin	N/A	N/A	-$381.64 million	($2.38)	-2.09

Generex Biotechnology has higher revenue and earnings than Acelyrin.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Generex Biotechnology and Acelyrin, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generex Biotechnology	0	0	0	0	N/A
Acelyrin	0	3	3	0	2.50

Acelyrin has a consensus target price of $10.83, indicating a potential upside of 117.54%.

Volatility and Risk

Generex Biotechnology has a beta of -0.07, indicating that its stock price is 107% less volatile than the S&P 500. Comparatively, Acelyrin has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500.

Summary

Generex Biotechnology beats Acelyrin on 5 of the 8 factors compared between the two stocks.

About Generex Biotechnology

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.

About Acelyrin

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.